MedTrace Logo

Effects of GLP-1 RAs on Human Lactation Outcomes

NCT07720414 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2026-07-22

No results posted yet for this study

Summary

There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.

The main questions the study will address are:

* Does GLP-1 RA-induced weight loss increase or decrease breastmilk production?
* Does GLP-1 RA-induced weight loss affect the nutritional composition of milk, including milk fat content?

Researchers will assess milk production rates before and after mothers begin taking injected GLP-1 RA medications to decrease their body weight. Weight loss will be confirmed with 7-day body weight averages.

Participants will:

* Weigh themselves and report measurements daily.
* Participate in 2-3 morning study visits over approx. 2.5-4.5 months (approx. 3-3.5hrs each).

During each visit, participants will:

* Use a study provided breastpump to express milk 3 times hourly for measurement of hourly milk production.
* Provide 1-3 oz of milk for further study.
* Answer questions about breastfeeding patterns.

Conditions

Interventions

DRUG

Injected GLP-1 Receptor Agonists and Dual Agonists

Participants are prescribed this medication by their care provider(s) as part of their postnatal clinical care, including but not limited to semaglutide and tirzepatide. The investigators do not provide, manage, or assign the medication.

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720414 on ClinicalTrials.gov